retatrutide phase 2 type 2 diabetes trial for Triple hormone receptor agonist metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide is gaining attention in – Lilly's triple agonist, retatrutide, demonstrated
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

























